May 3, 2023 07:10 PM EDT

“The grim veil has been lifted.” Excitement, and questions, mount over Lilly’s positive Alzheimer’s drug data

Ryan Cross

Senior Science Correspondent

Kyle LaHucik

Senior Reporter

Doctors, investors, and patient advocacy groups breathed a collective sigh of relief Wednesday morning after Eli Lilly broke its losing streak in its decades-long endeavor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

“The grim veil has been lifted.” Excitement, and questions, mount over Lilly’s positive Alzheimer’s drug data

Ryan Cross

Senior Science Correspondent

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

“The grim veil has been lift­ed.” Ex­cite­ment, and ques­tions, mount over Lil­ly’s pos­i­tive Alzheimer’s drug da­ta

Senior Science Correspondent

Senior Reporter

Sign up to read this article for free.

“The grim veil has been lifted.” Excitement, and questions, mount over Lilly’s positive Alzheimer’s drug data